This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort) (BOCLA-Mort)

This study has been completed.
Information provided by (Responsible Party):
Horst Neubauer, Ruhr University of Bochum Identifier:
First received: February 17, 2013
Last updated: February 24, 2013
Last verified: February 2013
Comparing standard treatment versus optimized antiplatelet therapy and outcomes measures.

Coronary Artery Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Optimized Antiplatelet Therapy With Aspirin and Clopidogrel Improves Mortality Compared to Standard Treatment.

Resource links provided by NLM:

Further study details as provided by Horst Neubauer, Ruhr University of Bochum:

Primary Outcome Measures:
  • Adverse cardiac events (MACE: mortality,rehospitalisation,myocardial infarction) [ Time Frame: Follow up for up to 12 months (retrospective analysis) ]

Enrollment: 600
Study Start Date: January 2009
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Standard therapy
Antiplatelet therapy following coronary stenting without platelet function testing
Optimized antiplatelet therapy

Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder.

Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)

Detailed Description:
The study is aimed to evaluate if optimized antiplatelet treatment using a test and treat algorithm (with whole blood aggregometry) is able to improve clinical outcome of patients compared to standard treatment without platelet function testing.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients following coronary stenting if informed consent was obtained

Inclusion Criteria:

  • coronary stent implantation

Exclusion Criteria:

  • no consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01796691

Cardiovascular Center, Ruhr-University Bochum
Bochum, NRW, Germany, D-44791
Sponsors and Collaborators
Ruhr University of Bochum
Principal Investigator: Horst Neubauer, MD Ruhr-University Bochum, Cardiovascular Center
  More Information

Responsible Party: Horst Neubauer, PHD, MD, Ruhr University of Bochum Identifier: NCT01796691     History of Changes
Other Study ID Numbers: BOCLAplan02
[Ruhr-University Bochum] ( Registry Identifier: F654R )
Study First Received: February 17, 2013
Last Updated: February 24, 2013

Keywords provided by Horst Neubauer, Ruhr University of Bochum:
low response
platelet aggregation
Acute Coronary Syndrome
Coronary Stent Implantation

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents processed this record on September 21, 2017